Prognostic significance of FLT3-ITD in pediatric acute myeloid leukemia: a meta-analysis of cohort studies

被引:20
作者
Wu, Xiaoli [1 ]
Feng, Xuefeng [2 ]
Zhao, Xiaoqing [1 ]
Ma, Futian [1 ]
Liu, Na [1 ]
Guo, Hongming [1 ]
Li, Chaonan [1 ]
Du, Huan [1 ]
Zhang, Baoxi [1 ]
机构
[1] Hebei Med Univ, Dept Pediat, Hosp 2, 215 West Heping Rd, Xinhua Dist 050000, Shijiazhuang, Peoples R China
[2] Hebei Med Univ, Dept Hematol, Hosp 2, Shijiazhuang 050000, Peoples R China
关键词
Acute myeloid leukemia; FLT3-ITD; Pediatric; Meta-analysis; PUBLICATION BIAS; MUTATIONS; CYTOGENETICS; INHIBITORS; NPM1;
D O I
10.1007/s11010-016-2775-1
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The purpose of the study was to assess the effect of the internal tandem duplication in FMS-like tyrosine kinase 3 (FLT3-ITD) on the outcome in pediatric acute myeloid leukemia (AML) patients. We identified eligible studies from several databases including PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) (from January 1995 to July 2015). Ten studies of 1661 pediatric patients with AML were included in exploring the relationship between the FLT3-ITD and overall survival (OS)/event free survival (EFS). Pediatric patients with AML with FLT3-ITD had worse OS [HR = 2.19 (1.60-3.01)]/EFS [HR = 1.70 (1.37-2.11)] than those patients without FLT3-ITD. Furthermore, FLT3-ITD had unfavorable effect on OS/EFS in the subgroups of NOS, uni/multivariate model, number of patients, the length of following-up, and patient source. The findings of this meta-analysis indicated that FLT3-ITD had negative impact on pediatric patients with AML.
引用
收藏
页码:121 / 128
页数:8
相关论文
共 33 条
[1]  
[Anonymous], ANN INTERNAL MED
[2]  
[Anonymous], 2008, PATHOLOGICA
[3]  
[Anonymous], J CLIN ONCOL
[4]  
[Anonymous], 2017, The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses
[5]   Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia [J].
Balgobind, Brian V. ;
Hollink, Iris H. I. M. ;
Arentsen-Peters, Susan T. C. J. M. ;
Zimmermann, Martin ;
Harbott, Jochen ;
Beverloo, H. Berna ;
von Bergh, Anne R. M. ;
Cloos, Jacqueline ;
Kaspers, Gertjan J. L. ;
de Haas, Valerie ;
Zemanova, Zuzana ;
Stary, Jan ;
Cayuela, Jean-Michel ;
Baruchel, Andre ;
Creutzig, Ursula ;
Reinhardt, Dirk ;
Pieters, Rob ;
Zwaan, C. Michel ;
van den Heuvel-Eibrink, Marry M. .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (10) :1478-1487
[6]   The incidence and clinical significance of nucleophosmin mutations in childhood AML [J].
Brown, Patrick ;
McIntyre, Emily ;
Rau, Rachel ;
Meshinchi, Soheil ;
Lacayo, Norman ;
Dahl, Gary ;
Alonzo, Todd A. ;
Chang, Myron ;
Arceci, Robert J. ;
Small, Donald .
BLOOD, 2007, 110 (03) :979-985
[7]   Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004 [J].
Creutzig, Ursula ;
Zimmermann, Martin ;
Bourquin, Jean-Pierre ;
Dworzak, Michael N. ;
Fleischhack, Gudrun ;
Graf, Norbert ;
Klingebiel, Thomas ;
Kremens, Bernhard ;
Lehrnbecher, Thomas ;
von Neuhoff, Christine ;
Ritter, Joerg ;
Sander, Annette ;
Schrauder, Andre ;
von Stackelberg, Arend ;
Stary, Jan ;
Reinhardt, Dirk .
BLOOD, 2013, 122 (01) :37-43
[8]  
Deeks JJ., 2011, COCHRANE HDB SYSTEMA, V5
[9]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188
[10]   Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet [J].
Doehner, Hartmut ;
Estey, Elihu H. ;
Amadori, Sergio ;
Appelbaum, Frederick R. ;
Buechner, Thomas ;
Burnett, Alan K. ;
Dombret, Herve ;
Fenaux, Pierre ;
Grimwade, David ;
Larson, Richard A. ;
Lo-Coco, Francesco ;
Naoe, Tomoki ;
Niederwieser, Dietger ;
Ossenkoppele, Gert J. ;
Sanz, Miguel A. ;
Sierra, Jorge ;
Tallman, Martin S. ;
Loewenberg, Bob ;
Bloomfield, Clara D. .
BLOOD, 2010, 115 (03) :453-474